Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

MLA

Mazur, Pawel K., et al. “Combined Inhibition of BET Family Proteins and Histone Deacetylases as a Potential Epigenetics-Based Therapy for Pancreatic Ductal Adenocarcinoma.” Nature Medicine, vol. 21, no. 10, Oct. 2015, pp. 1163–71. EBSCOhost, https://doi.org/10.1038/nm.3952.

APA

Mazur, P. K., Herner, A., Mello, S. S., Wirth, M., Hausmann, S., Sánchez-Rivera, F. J., Lofgren, S. M., Kuschma, T., Hahn, S. A., Vangala, D., Trajkovic-Arsic, M., Gupta, A., Heid, I., Noël, P. B., Braren, R., Erkan, M., Kleeff, J., Sipos, B., Sayles, L. C., … Siveke, J. T. (2015). Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 21(10), 1163–1171. https://doi.org/10.1038/nm.3952

Chicago

Mazur, Pawel K, Alexander Herner, Stephano S Mello, Matthias Wirth, Simone Hausmann, Francisco J Sánchez-Rivera, Shane M Lofgren, et al. 2015. “Combined Inhibition of BET Family Proteins and Histone Deacetylases as a Potential Epigenetics-Based Therapy for Pancreatic Ductal Adenocarcinoma.” Nature Medicine 21 (10): 1163–71. doi:10.1038/nm.3952.